Compare ARK Space & Defense Innovation ETF (ARKX) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs Quest Diagnostics Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $34.7, while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while ARK Space & Defense Innovation ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | DGX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $238.50 |
52-Week Low | $25.46 | $173.49 |
Market Cap | — | $26.21B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space & Defense Innovation ETF (ARKX) trades at $34.8, up 1.13% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on space economy exposure, including holdings like SpaceX (8.31%) and Rocket Lab (6.27%), benefiting from growing commercial and defense space investments. Recent news highlights competition with other space ETFs and the impact of SpaceX's IPO on the sector.
Outlook remains positive due to thematic tailwinds in space innovation, but high volatility and stretched valuations in key holdings pose risks. Investors gain diversified access to a high-growth theme, though expense ratios and sector concentration require careful consideration amid market fluctuations.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
